Scientists at the National Institutes of Health (NIH) have found that two common types of hormone therapy may alter breast ...

Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces that the U.S. Food and ...

The relationship between hormone therapy (oestrogen with or without progestogen) and breast cancer risk has been widely ...

Scientists at the National Institutes of Health (NIH) have found that two common types of hormone therapy may alter breast ...

Using some types of HRT before the menopause could increase the risk of breast cancer in young women, a study suggests. The ...

Diagnosis and treatment of breast cancer can differ for patients in rural communities compared with those in urban ...

A new discovery by the Cold Spring Harbor Laboratory could help point toward the first effective therapy for triple-negative breast cancer. Triple-negative breast cancer accounts for 10 to 15% of all ...

Breast cancer is one of the most common cancers among women in the United States. Thanks to decades of fundamental research, ...

Panelists discuss the evolving management of estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer, ...

All patients will also receive standard doses of darolutamide. Phase 2 Clinical Trial in HER2+ Metastatic Breast Cancer In this investigator-sponsored Phase 2 clinical trial, 44 patients with ...